Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY008211A in Hepatic Impairment
NCT07625618Phase 1Completed
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of MY-008 (3 arms), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration up to 12 weeks, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration up to 12 weeks and 1 more. Started Sep 2024; status: completed.
02
Drugs
MY-008
Beyond the preview
Go deeper on NCT07625618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07625618.